Arcellx Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Arcellx Inc (ACLX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Arcellx Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 22M vs 266,111M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-70.3% annualized vs trailing 12 months), vs accelerating (+66.5%) for its tracked peer group.
- Growth: Arcellx Inc generated -89.2% revenue growth year over year in Q4 2025, vs 8.1% for its tracked competitors combined.
- Profitability: Its -3,513.4% net margin compares with 19.1% for the peer group.
- Peer revenue share: Arcellx Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.11M compares with $1.27M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ACLX Sales vs. its Competitors, Q4 2025
Arcellx Inc reported revenue contraction of 89.17 % year on year in Q4 2025, below its competitors' combined revenue growth of 8.06 %.
With a net margin of -3,513.42 %, Arcellx Inc reported lower profitability than its competitors (19.05 %).
Arcellx Inc generated 0.00 % of the combined sales of its peer group, down from 0.01 % a year earlier.
Arcellx Inc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Arcellx Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Arcellx Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Arcellx Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (22) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Arcellx Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.1% year over year, combined, vs -89.2% for Arcellx Inc. Arcellx Inc's share of combined industry revenue moved from 0.04% to 0.00%, a loss of 0.04 percentage points.
Arcellx Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Arcellx Inc | - | No | No | Yes |
| Competitors combined (40) | ||||
| High-Confidence Competitors (26) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ACLX Stock Performance relative to its Competitors
ACLX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 2 | Revolution Medicines Inc | 282.9% | Outperformed |
| 3 | Immix Biopharma Inc | 282.9% | Outperformed |
| 4 | Kymera Therapeutics Inc | 282.9% | Outperformed |
| 5 | Biogen Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Arcellx Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Arcellx Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Arcellx Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Arcellx Inc | 6,479.07 | 22.29 |
| Abbvie Inc | 511,783.58 | 64,386.00 |
| Novartis Ag | 300,366.20 | 56,674.00 |
| Amgen Inc | 238,783.36 | 38,095.00 |
| Gilead Sciences Inc | 194,541.93 | 30,457.00 |
| Vertex Pharmaceuticals Inc | 131,338.68 | 12,587.20 |
| SUBTOTAL | 1,644,546.46 | 266,151.64 |
Sign in to see all competitors of Arcellx Inc .
Sources: Arcellx Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Arcellx Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Arcellx Inc's Competitors Named by the Company
Competitive relationships identified from Arcellx Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Immix | Company report | 85% |
| Legend | Company report | 85% |
| Celyad | Company report | 85% |
| Kyverna | Company report | 85% |
| Precision BioSciences | Company report | 85% |
| AbbVie | Company report | 85% |
| Legend | Company report | 85% |
| Bristol Myers Squibb | Company report | 85% |
| Cellectis | Company report | 85% |
| Gilead | Company report | 85% |
| Kelonia | Company report | 85% |
| Novartis | Company report | 85% |
| Roche | Company report | 85% |
| AstraZeneca | Company report | 85% |
| CARsgen | Company report | 85% |
| Crispr | Company report | 85% |
| Innovent | Company report | 85% |
| Pregene | Company report | 85% |
| Allogene | Company report | 85% |
| Cabaletta | Company report | 85% |
| Cellular Biomedicine Group | Company report | 85% |
| GSK | Company report | 85% |
| Pfizer | Company report | 85% |
| Tempest Therapeutics Inc | Company report | 85% |
| Autolus | Company report | 85% |
| Cartesian | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Nanjing IASO Biotherapeutics Ltd | Company report | 85% |
| Regeneron | Company report | 85% |
| Amgen | Company report | 85% |
| Caribou Biosciences | Company report | 85% |
| Kite | Company report | 85% |
| Generon | Company report | 85% |
Company report basis, confidence, active dates and source counts for Arcellx Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Arcellx Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Arcellx Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Arcellx Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Arcellx Inc | 6,479 | 106,632 | -1,095,378 |
| Abbvie Inc | 511,784 | 1,129,579 | 110,807 |
| Novartis Ag | 300,366 | 752,973 | 185,566 |
| Amgen Inc | 238,783 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 194,542 | 1,791,588 | -190,588 |
| Vertex Pharmaceuticals Inc | 131,339 | 31,079,506 | 10,877,037 |
| PEERS TOTAL | 1,638,067 | 1,266,939 | 179,496 |
Arcellx Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Exelixis Inc | United States 91.44 % |
| Iovance Biotherapeutics inc | US 98.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Arcellx Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Arcellx Inc's industry classification, broader than the peer set above. Market cap in millions of $.Arcellx Inc ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,335, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 235,620 | 25.97 % |
| 2 | Gilead Sciences Inc | 194,971 | 21.49 % |
| 3 | Moderna Inc | 88,529 | 9.76 % |
| 4 | Argenx Se | 56,951 | 6.28 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Mesoblast Limited | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Arcellx Inc | 6,511 | 0.00 % |
Market cap and industry share for the rest of Arcellx Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-15.
Arcellx Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (160 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 39.10 % (avg) | -39.1 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -1.50 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 10.44 % | 9.14 % (avg) | +1.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Arcellx Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 22.7x | - |
| EV / EBITDA | - | 17.6x | - |
| P/B | 10.9x | 5.0x | +5.9x |
| Return on Equity | -55.42 % | industry aggregate | -65.80 % |
| Return on Invested Capital | -27.20 % | -5.14 % (avg) | -22.06 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Arcellx Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | - | -2.16 % | -79.35 % |
| Operating Margin | - | -81.47 % | - | - |
| Return on Invested Capital | -35.99 % | -10.51 % | -12.36 % | -27.20 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Arcellx Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,335 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 10.44 % vs industry average 9.14 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Arcellx Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Arcellx Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Arcellx Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 65.8 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-70.3% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (35.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Arcellx Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Arcellx Inc | 0.66 | 4.27 | - |
| Abbvie Inc | 0.16 | 0.75 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Arcellx Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Arcellx Inc | Q4 2025 | -89.2 % | - |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| PEERS TOTAL | +9.5 % | -25.4 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Arcellx Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Arcellx Inc | Q4 2025 | - | -49.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
Arcellx Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Arcellx Inc | - | - | - |
| Abbvie Inc | 4.68% | 9.11% | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Arcellx Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Arcellx Inc | - | 290.72 |
| Abbvie Inc | 81.63 | 7.95 |
| Novartis Ag | 21.48 | 5.30 |
| Amgen Inc | 27.26 | 6.27 |
| Gilead Sciences Inc | - | 6.39 |
| Vertex Pharmaceuticals Inc | 30.01 | 10.43 |
| PEERS AVERAGE | 43.88 | 6.18 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.